TIMs, TAMs, and PS- antibody targeting: Implications for cancer immunotherapy

Adam S. Dayoub, Rolf A. Brekken

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Immunotherapy for cancer is making impressive strides at improving survival of a subset of cancer patients. To increase the breadth of patients that benefit from immunotherapy, new strategies that combat the immunosuppressive microenvironment of tumors are needed. Phosphatidylserine (PS) signaling is exploited by tumors to enhance tumor immune evasion and thus strategies to inhibit PS-mediated immune suppression have potential to increase the efficacy of immunotherapy. PS is a membrane lipid that flips to the outer surface of the cell membrane during apoptosis and/or cell stress. Externalized PS can drive efferocytosis or engage PS receptors (PSRs) to promote local immune suppression. In the tumor microenvironment (TME) PS-mediated immune suppression is often termed apoptotic mimicry. Monoclonal antibodies (mAbs) targeting PS or PSRs have been developed and are in preclinical and clinical testing. The TIM (T-cell/transmembrane, immunoglobulin, and mucin) and TAM (Tyro3, AXL, and MerTK) family of receptors are PSRs that have been shown to drive PS-mediated immune suppression in tumors. This review will highlight the development of mAbs targeting PS, TIM-3 and the TAM receptors.

Original languageEnglish (US)
Article number29
JournalCell Communication and Signaling
Issue number1
StatePublished - Feb 22 2020


  • Antibody
  • Cancer
  • Clinical trial
  • Immunotherapy
  • Oncology
  • Phosphatidylserine
  • TAM
  • TIM
  • Treatment
  • Tumor
  • Tumor

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'TIMs, TAMs, and PS- antibody targeting: Implications for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this